Market by Type, Market by Type, Condition, Therapeutic Type, Delivery Method, Channel, and Country Outlook | Forecast 2023-2030
Triton’s research report states that the Europe ophthalmic drugs market is expected to generate revenue at a CAGR of 6.25% over the forecast period 2023-2030.
Report scope can be customized per your requirements - Request Free Sample Report
The countries studied in this region include:
•        United
Kingdom
•        Germany
•        France
•        Italy
•      Â
Spain
•       Poland
•        Rest
of Europe
The European
ophthalmic drugs market is witnessing a dynamic shift due to aging demographics,
commitment to the healthcare sector, and pharmaceutical innovations which
propels the need for using ophthalmic medications. The future of the studied
market seems promising as several companies look forward to collaborating and
developing patient-centric medicines. The advancements in medical science and research
incentives also create a conducive environment for the growth of the ophthalmic
drugs market.
The United Kingdom (UK) holds the highest share in Europe. This is due to an added importance for the healthcare system with regular checkups and early detection of eye diseases. These initiatives lead to a higher awareness among patients to seek early treatment to cure eye disorders. Moreover, the innovations and advancements in drug delivery and treatment options offer convenient ways to manage eye conditions for patients. All these factors together drive the ophthalmic drugs market’s growth in the UK.Â
The growth of the ophthalmic drugs market in Italy is attributed
to technological innovation, patient-centric eye care for the aging population,
and strategic collaborations. A rise in ophthalmic treatments also includes
gene therapies and regenerative medicines, which require the usage of
ophthalmic drugs. The regulatory standards by the Italian Medicines Agency
ensure that manufacturers strictly comply with the norms and maintain quality
assurance of ophthalmic products. Additionally, the awareness of telemedicine
and e-health services influences the ophthalmic drugs market.
A
higher prevalence of dry eye is found in urban areas, especially among the adult
population having sedentary lifestyles. The treatment of dry eye involves
medication in the form of artificial tears, prescriptions, and lifestyle
modifications to address insufficient tear production and preserve eye health. The ophthalmic
drugs market is segmented based on type, condition, delivery method,
therapeutic type, and channel. The condition segment is categorized into dry
eye, glaucoma, retinal disorders, infection, and other conditions.
The key
companies in the ophthalmic drugs
market
are Pfizer Inc, Sun Pharmaceutical
Industries Ltd, Thea Pharma Inc, Novartis AG,
AbbVie Inc, Bausch Health Companies Inc, Regeneron Pharmaceuticals Inc,
Accutome Inc, Genentech Inc, and Johnson & Johnson.
Pfizer
Inc is a biopharmaceutical company involved in developing and manufacturing
products to treat cancer, inflammation, immune disorders, cardiovascular,
metabolic, pain, and rare diseases. The company sells its products in Europe,
Africa, South America, Asia-Pacific, and North America. It is headquartered in New
York, the United States, with manufacturing facilities in Italy, Germany,
Ireland, etc.
KEY
DELIVERABLES OF THE REPORT:
â—ŹÂ Â Â Â Â
Market CAGR during the forecasting years 2023-2030
â—ŹÂ Â Â Â Â
Detailed data highlighting key insights, industry components, and
market strategies
â—ŹÂ Â Â Â Â
Comprehensive information and estimation of the ophthalmic
drugs
market revenue growth in Europe and its influence on the parent market
â—ŹÂ Â Â Â Â
In-depth study of forthcoming trends in consumer behavioral
patterns
â—ŹÂ Â Â Â Â
A meticulous analysis of the competitive landscape, vendor
scorecard, and Porter’s Five Forces
â—ŹÂ Â Â Â Â
A wide-ranging study of factors that will challenge the Europe
ophthalmic drugs
market’s growth during the upcoming years
Want to get specific insights? Our team of
analysts can customize this report based on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1.   EUROPE
OPHTHALMIC DRUGS MARKET - SUMMARY
2.   INDUSTRY
OUTLOOK
2.1. TECHNOLOGY
SNAPSHOT
2.2. IMPACT
ANALYSIS ON THE OPHTHALMIC DRUGS MARKET
2.2.1. COVID-19
IMPACT ON THE OPHTHALMIC DRUGS MARKET
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. MARKET
MATURITY ANALYSIS
2.5. REGULATORY
FRAMEWORK
2.6. KEY
BUYING IMPACT ANALYSIS
2.7. KEY
MARKET STRATEGIES
2.7.1. COLLABORATIONS
2.7.2. PRODUCT
LAUNCHES
2.7.3. MERGERS
& ACQUISITIONS
2.8. MARKET
DRIVERS
2.8.1. AGING
POPULATION VULNERABLE TO EYE DISORDERS
2.8.2. PROGRESS
IN DRUG DELIVERY TECHNOLOGIES
2.8.3. ESCALATING
INCIDENCE OF OCULAR DISEASES
2.8.4. REIMBURSEMENT
POLICIES BY HEALTHCARE SYSTEMS
2.9. MARKET
CHALLENGES
2.9.1. CHALLENGING
TIMELINES FOR PRODUCT APPROVAL
2.9.2. ADVERSE
EFFECTS ASSOCIATED WITH OPHTHALMIC DRUG USAGE
2.10. MARKET
OPPORTUNITIES
2.10.1. SURGE
IN INTEREST REGARDING TOPICALLY ADMINISTERED OPHTHALMIC DRUGS
2.10.2. INCREASE
IN APPROVALS FOR INNOVATIVE OPHTHALMIC THERAPIES
2.11. ANALYST
PERSPECTIVE
3.   EUROPE
OPHTHALMIC DRUGS MARKET – BY TYPE
3.1. PRESCRIPTION
DRUGS
3.2. OVER-THE-COUNTER
DRUGS
4.   EUROPE
OPHTHALMIC DRUGS MARKET – BY CONDITION
4.1. DRY
EYE
4.2. GLAUCOMA
4.3. INFECTION/INFLAMMATION/ALLERGIES
4.4. RETINAL
DISORDER
4.4.1. WET-AGE
RELATED MACULAR DEGENERATION
4.4.2. DRY-AGE
RELATED MACULAR DEGENERATION
4.4.3. DIABETIC
RETINOPATHY
4.4.4. OTHER
RETINAL DISORDERS
4.5. OTHER
CONDITIONS
5.   EUROPE
OPHTHALMIC DRUGS MARKET – BY THERAPEUTIC TYPE
5.1. ANTI-GLAUCOMA
5.2. ANTI-INFECTION
5.3. ANTI-INFLAMMATORY
5.4. ANTI-ALLERGY
5.5. OTHER
THERAPEUTIC TYPES
6.   EUROPE
OPHTHALMIC DRUGS MARKET – BY DELIVERY METHOD
6.1. GELS
6.2. EYE
SOLUTIONS & SUSPENSIONS
6.3. CAPSULES
& TABLETS
6.4. EYE
DROPS
6.5. OINTMENTS
7.   EUROPE
OPHTHALMIC DRUGS MARKET – BY CHANNEL
7.1. HOSPITAL
PHARMACIES
7.2. DRUG
STORES
7.3. ONLINE
PHARMACIES
7.4. OTHER
CHANNELS
8.   EUROPE
OPHTHALMIC DRUGS MARKET – COUNTRY OUTLOOK
8.1. UNITED
KINGDOM
8.1.1. UNITED
KINGDOM OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.2. GERMANY
8.2.1. GERMANY
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.3. FRANCE
8.3.1. FRANCE
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.4. ITALY
8.4.1. ITALY
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.5. SPAIN
8.5.1. SPAIN
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.6. POLAND
8.6.1. POLAND
OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
8.7. REST
OF EUROPE
8.7.1. REST
OF EUROPE OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS
9.   COMPETITIVE
LANDSCAPE
9.1. ABBVIE
INC
9.1.1. OVERVIEW
9.1.2. PRODUCT
PORTFOLIO
9.1.3. KEY
STRENGTHS
9.1.4. KEY
CHALLENGES
9.2. BAUSCH
HEALTH COMPANIES INC
9.2.1. OVERVIEW
9.2.2. PRODUCT
PORTFOLIO
9.2.3. KEY
STRENGTHS
9.2.4. KEY
CHALLENGES
9.3. JOHNSON
& JOHNSON
9.3.1. OVERVIEW
9.3.2. PRODUCT
PORTFOLIO
9.3.3. KEY
STRENGTHS
9.3.4. KEY
CHALLENGES
9.4. NOVARTIS
AG
9.4.1. OVERVIEW
9.4.2. PRODUCT
PORTFOLIO
9.4.3. KEY
STRENGTHS
9.4.4. KEY
CHALLENGES
9.5. REGENERON
PHARMACEUTICALS INC
9.5.1. OVERVIEW
9.5.2. PRODUCT
PORTFOLIO
9.5.3. KEY
STRENGTHS
9.5.4. KEY
CHALLENGES
9.6. SUN
PHARMACEUTICAL INDUSTRIES LTD
9.6.1. OVERVIEW
9.6.2. PRODUCT
PORTFOLIO
9.6.3. KEY
STRENGTHS
9.6.4. KEY
CHALLENGES
9.7. ACCUTOME
INC
9.7.1. OVERVIEW
9.7.2. PRODUCT
PORTFOLIO
9.7.3. KEY
STRENGTHS
9.7.4. KEY
CHALLENGES
9.8. GENENTECH
INC
9.8.1. OVERVIEW
9.8.2. PRODUCT
PORTFOLIO
9.8.3. KEY
STRENGTHS
9.8.4. KEY
CHALLENGES
9.9. THEA
PHARMA INC
9.9.1. OVERVIEW
9.9.2. PRODUCT
PORTFOLIO
9.9.3. KEY
STRENGTHS
9.9.4. KEY CHALLENGES
9.10. PFIZER
INC
9.10.1. OVERVIEW
9.10.2. PRODUCT
PORTFOLIO
9.10.3. KEY
STRENGTHS
9.10.4. KEY
CHALLENGES
10. RESEARCH
METHODOLOGY & SCOPE
10.1. RESEARCH
SCOPE & DELIVERABLES
10.2. SOURCES
OF DATA
10.3. RESEARCH
METHODOLOGY
TABLE 1: EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2023-2030
(IN $ MILLION)
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: LIST OF COLLABORATIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF MERGERS & ACQUISITIONS
TABLE 6: EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2023-2030
(IN $ MILLION)
TABLE 7: EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $
MILLION)
TABLE 8: EUROPE OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030 (IN $
MILLION)
TABLE 9: EUROPE OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030
(IN $ MILLION)
TABLE 10: EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2023-2030
(IN $ MILLION)
TABLE 11: EUROPE OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2023-2030
(IN $ MILLION)
TABLE 12: EUROPE OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030 (IN $
MILLION)
FIGURE 1: TECHNOLOGY SNAPSHOT
FIGURE 2: MARKET MATURITY ANALYSIS
FIGURE 3: EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2022 & 2030 (IN %)
FIGURE 4: EUROPE OPHTHALMIC DRUGS MARKET, BY PRESCRIPTION DRUGS,
2023-2030 (IN $ MILLION)
FIGURE 5: EUROPE OPHTHALMIC DRUGS MARKET, BY OVER-THE-COUNTER DRUGS,
2023-2030 (IN $ MILLION)
FIGURE 6: EUROPE OPHTHALMIC DRUGS MARKET, BY CONDITION, 2022 & 2030
(IN %)
FIGURE 7: EUROPE OPHTHALMIC DRUGS MARKET, BY DRY EYE, 2023-2030 (IN $
MILLION)
FIGURE 8: EUROPE OPHTHALMIC DRUGS MARKET, BY GLAUCOMA, 2023-2030 (IN $
MILLION)
FIGURE 9: EUROPE OPHTHALMIC DRUGS MARKET, BY
INFECTION/INFLAMMATION/ALLERGIES, 2023-2030 (IN $ MILLION)
FIGURE 10: EUROPE OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030
(IN $ MILLION)
FIGURE 11: EUROPE OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2022
& 2030 (IN %)
FIGURE 12: EUROPE OPHTHALMIC DRUGS MARKET, BY WET AGE-RELATED MACULAR
DEGENERATION, 2023-2030 (IN $ MILLION)
FIGURE 13: EUROPE OPHTHALMIC DRUGS MARKET, BY DRY AGE-RELATED MACULAR
DEGENERATION, 2023-2030 (IN $ MILLION)
FIGURE 14: EUROPE OPHTHALMIC DRUGS MARKET, BY DIABETIC RETINOPATHY,
2023-2030 (IN $ MILLION)
FIGURE 15: EUROPE OPHTHALMIC DRUGS MARKET, BY OTHER RETINAL DISORDERS,
2023-2030 (IN $ MILLION)
FIGURE 16: EUROPE OPHTHALMIC DRUGS MARKET, BY OTHER CONDITIONS, 2023-2030
(IN $ MILLION)
FIGURE 17: EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2022
& 2030 (IN %)
FIGURE 18: EUROPE OPHTHALMIC DRUGS MARKET, BY ANTI-GLAUCOMA, 2023-2030
(IN $ MILLION)
FIGURE 19: EUROPE OPHTHALMIC DRUGS MARKET, BY ANTI-INFECTION, 2023-2030
(IN $ MILLION)
FIGURE 20: EUROPE OPHTHALMIC DRUGS MARKET, BY ANTI-INFLAMMATORY,
2023-2030 (IN $ MILLION)
FIGURE 21: EUROPE OPHTHALMIC DRUGS MARKET, BY ANTI-ALLERGY, 2023-2030 (IN
$ MILLION)
FIGURE 22: EUROPE OPHTHALMIC DRUGS MARKET, BY OTHER THERAPEUTIC TYPES,
2023-2030 (IN $ MILLION)
FIGURE 23: EUROPE OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2022 &
2030 (IN %)
FIGURE 24: EUROPE OPHTHALMIC DRUGS MARKET, BY GELS, 2023-2030 (IN $
MILLION)
FIGURE 25: EUROPE OPHTHALMIC DRUGS MARKET, BY EYE SOLUTIONS &
SUSPENSIONS, 2023-2030 (IN $ MILLION)
FIGURE 26: EUROPE OPHTHALMIC DRUGS MARKET, BY CAPSULES & TABLETS,
2023-2030 (IN $ MILLION)
FIGURE 27: EUROPE OPHTHALMIC DRUGS MARKET, BY EYE DROPS, 2023-2030 (IN $
MILLION)
FIGURE 28: EUROPE OPHTHALMIC DRUGS MARKET, BY OINTMENTS, 2023-2030 (IN $
MILLION)
FIGURE 29: EUROPE OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2022 & 2030
(IN %)
FIGURE 30: EUROPE OPHTHALMIC DRUGS MARKET, BY HOSPITAL PHARMACIES,
2023-2030 (IN $ MILLION)
FIGURE 31: EUROPE OPHTHALMIC DRUGS MARKET, BY DRUG STORES, 2023-2030 (IN
$ MILLION)
FIGURE 32: EUROPE OPHTHALMIC DRUGS MARKET, BY ONLINE PHARMACIES,
2023-2030 (IN $ MILLION)
FIGURE 33: EUROPE OPHTHALMIC DRUGS MARKET, BY OTHER CHANNELS, 2023-2030
(IN $ MILLION)
FIGURE 34: EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2022 &
2030 (IN %)
FIGURE 35: UNITED KINGDOM OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $
MILLION)
FIGURE 36: GERMANY OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)
FIGURE 37: FRANCE OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)
FIGURE 38: ITALY OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)
FIGURE 39: SPAIN OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)
FIGURE 40: POLAND OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)
FIGURE 41: REST OF EUROPE OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $
MILLION)